The new NIH website offers insights into emotional, physical, and financial aspects of terminal care.
Labs suffered loss of momentum with their research and grant applications were pushed back to November as a consequence of the United States government shutdown.
A new optical imaging technology could give doctors new ways to both identify breast cancer and to monitor the responses of individual patients to initial treatments of the disease. Tufts Medical Center in Boston is now undertaking a five-year clinical study of the procedure through a $3.5 million grant from the National Institutes of Health.
Sign Up for Free e-newsletters
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- When There Are No Words: Interpreting Patients' and Families' Subtle Messages
- Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|